Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

178 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-20

Study Completion Date

2022-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In France, the second cancer plan of 2009-2013 aimed to strengthen the role of MT by putting it back at the center of patient monitoring, in particular by asking "regional health agencies to encourage and support local experiments" which aim for better coordination between the city and the hospital. The third cancer plan for 2014-2019 insists on this measure because it had proven to be unproductive, and recommends, in addition to the creation of a nurse dedicated to the coordination of care between community medicine and the hospital, the creation of a direct telephone line to reach the hospital medical team. This measure is mainly aimed at the follow-up of certain cancers that do not require the technical support of the hospital, as is the case in the post-operative follow-up of RCC and CaP, where the additional examinations carried out during follow-up are carried out in the city.

The research hypothesis is that this new method of monitoring had a positive impact on care in terms of quality, accessibility, organization and costs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.

NCT05415787

Circulating Tumor DNA Metastatic Prostate Cancer

COMPLETED

PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer

NCT04983459

Prostatic Neoplasms Recurrence

COMPLETED

Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer

NCT05333432

Prostate Cancer

WITHDRAWN NA

PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing

NCT06460454

Prostate Cancer

COMPLETED

Transperineal, MRI-guided, Prostate Biopsy

NCT02651948

Prostate Cancer

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Kidney Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult subjects (≥18 years old)
* Patient operated on for localized prostate or kidney cancer
* Patient followed at the HUS during the period from 01/01/2015 to 12/31/2021
* Subject who has not expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion Criteria

* Subject having expressed opposition to participating in the study
* Patient under active therapy (hormonotherapy, systemic treatment) for the pathology studied
* Impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.)
* Subject under judicial protection
* Subjects under guardianship or curatorship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No